RMC No. 110-2022: VAT Exemption Updates for Certain Cancer and COVID-19 Medicines Under the CREATE Act

RMC No. 110-2022 updates VAT-exempt medicines under CREATE, covering certain cancer and COVID-19 medicines effective upon FDA publication. Businesses selling, purchasing, importing, prescribing, or accounting for medicines used in cancer and COVID-19 treatment must verify whether the specific medicines they handle are now included in the updated List of VAT-Exempt Medicines. RMC No. 110-2022 matters […]

RMC No. 59-2022: VAT-Exempt Medicines for Cancer and COVID-19 Treatment Under the CREATE Act

RMC No. 59-2022 updates the VAT-exempt medicine list under CREATE to include certain cancer and COVID-19 treatment medicines. Businesses selling, purchasing, prescribing, distributing, or accounting for qualified medicines for cancer and COVID-19 treatment must check whether their products are covered by the updated List of VAT-Exempt Medicines under Republic Act No. 11534, or the CREATE […]

RMC No. 51-2022: Updated VAT-Exempt Medicines for COVID-19, Hypertension, and Cancer Under the CREATE Act

RMC No. 51-2022 updates the CREATE Act VAT-exempt medicine list for COVID-19, hypertension, and a corrected cancer medicine entry. Businesses dealing in covered medicines should immediately check whether their invoicing, VAT treatment, product master files, and pharmacy or distribution records reflect the latest VAT-exempt medicine list recognized for CREATE Act purposes. RMC No. 51-2022 confirms […]